The Bombay Burmah Trading Corporation (501425) Q4 97/98 earnings summary
Event summary combining transcript, slides, and related documents.
Q4 97/98 earnings summary
22 Oct, 2026Executive summary
FY 1997-98 profit after tax rose to Rs. 808.86 lakhs from Rs. 739.02 lakhs; improved tea and coffee realisations supported higher gross profit before depreciation and prior-year excise duty.
Recommended dividend of 26% (Rs. 2.60 per share); commercial production began at Central India Board Products and Afcoset Scales.
Financial highlights
Gross income was Rs. 13,833.52 lakhs versus Rs. 11,068.64 lakhs; sales were Rs. 13,083.41 lakhs versus Rs. 9,967.34 lakhs.
Gross profit before depreciation and excise duty for earlier years increased to Rs. 1,898.62 lakhs from Rs. 1,252.55 lakhs; Rs. 362.65 lakhs of prior-period excise duty was charged.
Profit before tax was Rs. 1,070.86 lakhs versus Rs. 956.92 lakhs; profit after tax was Rs. 808.86 lakhs versus Rs. 739.02 lakhs.
Interest expense increased to Rs. 958.19 lakhs from Rs. 777.02 lakhs; depreciation was Rs. 465.11 lakhs versus Rs. 295.63 lakhs.
Outlook and guidance
BCL Springs was expected to improve performance in FY 1998-99; Afcoset Balances outlook was favourable.
Central India Board Products was expanding pre-laminated board capacity; its commercial production began during the year.
Latest events from The Bombay Burmah Trading Corporation
- Higher profit, softer sales and negative operating cash flow defined FY 1996-97.501425
Q4 96/97 - Labor disruption and particle-board losses drove a steep FY99 profit decline.501425
Q4 98/99 - Labour disruption, cost inflation and tea-price pressure drove a sharp loss.501425
Q4 99/00 - Commodity-price pressure and estate disruptions drove another loss; the dividend was skipped.501425
Q4 01/02 - Profit returned as operational gains offset weak tea and coffee markets.501425
Q4 02/03 - Profit rebounded as lower financing costs and industrial gains offset plantation pressures.501425
Q4 03/04 - Higher profits and associate earnings met drought, cost and currency pressures.501425
Q4 04/05 - FY06 profit rose amid cost pressure, with expansion and healthcare poised to drive growth.501425
Q4 05/06 - Standalone earnings improved; acquisitions and new capacity set up growth, with VRS costs deferred to FY08.501425
Q4 06/07